62 results about "Tropane" patented technology

The present invention is related to a compound of formula (I)

wherein R_1a, R_1b, R_1c, R_1d, R_2a, R_2b, R₃, R₄, p, r and are as defined herein, its preparation, pharmaceutical composition and use as a modulator of the activity of the 11β-hydroxysteroid dehydrogenase type 1 (11βHSD1).

The invention relates to a citric acid tropisetron raw material medicine and a preparation technology of the citric acid tropisetron raw material medicine and an injection liquid, and belongs to the field of chemical pharmacy; in the process of tropisetron salifying, the citric acid is used as acid radical; the chemical name of the citric acid tropane tropisetron is [(1alpha H, 5alpha H)-8-methyl-azepine bicyclo-(3, 2, 1) octyl group-3alpha-]-1H- benzpyrole-3- formic ether citrate; and the molecular formula is C23H28N209. In the process of tropisetron salifying, the tropisetron is dissolved in ethanol; the mixture is added with ethanol solution of the citric acid, evenly stirred and stands till the needed solid is separated out; the crude citric acid tropisetron is filtered, heated and dissolved in distilled water, is added with the activated carbon for backflowing and decoloring, cools and stands after being filtered so as to separate out white cystal; the mixture is filtered; the filter cake is dried and then distilled water is used for the secondary recrystallization to obtain the refined citric acid tropane tropisetron. The clinical research shows that compared with the imported muriatic acid tropisetron injection solution, the citric acid tropisetron injection solution has similar curative effect and safety.

Accordingly, the invention relates to a pharmaceutical composition comprising a monoamine neurotransmitter re-uptake inhibitor comprising a 2,3-disubstituted tropane moiety, or a tautomer, a pharmaceutically acceptable salt, solvate, or physiologically functional derivative thereof, and at least one NMDA receptor antagonists or a pharmaceutically acceptable salt, solvate, or physiologically functional derivative thereof.

The conventional anticholinergic drugs for administration through inhalation have been considered to have the possibility of aggravating dysuria associated with prostatic hyperplasia mediated by blood, and it has been demanded that the conventional anticholinergic drugs for administration through inhalation will have to show reduced side effects or adverse reactions.

The present invention relates to a compound represented by the general formula (I):

(wherein A represents;

and R¹, R², R³ and R¹ each a hydrogen atom or a substituent; R⁵ is a substituent; X⁻ is an anion; the symbol:

denotes an exo-form or endo-form, or their mixture), its salt or solvation product thereof. They are useful as a prophylactic and/or therapeutic agent with reduced side effects or adverse reactions for the diseases mediated by the muscarinic receptor.

The invention relates to a pharmaceutical composition comprising a monoamine neurotransmitter re-uptake inhibitor comprising a 2,3-disubstituted tropane moiety, or a tautomer, a pharmaceutically acceptable salt, solvate, or physiologically functional derivative thereof, and at least one acetylcholinesterase inhibitor or a pharmaceutically acceptable salt, solvate, or physiologically functional derivative thereof, and a pharmaceutically acceptable carrier or excipient, and optionally one or more other therapeutic ingredients.

The present invention relates to tropane derivatives having particular use for the in vivo detection of dopamine transporters.These derivatives meet the formulain which R1 is I or Sn (R3)3, R2 is for example the methyl group, and X and Y are various substituents.The derivatives with X=CH3 and Y=H show strong specificity for the dopamine transporter compared with the serotonin transporter (74% inhibition when the transporter is previously saturated with GBR 12909).

The invention relates to an ophthalmic in-situ jelly of chiral anti-glaucoma medicine levofloxacin tropane. The ophthalmic jellies concretely comprises 0.03 percent to 0.3 percent of levofloxacin tropane, 10 percent to 20 percent of hydrophilic polymer material, 0 percent to 20 percent of humectant, 0.1 percent to 10 percent of permeation pressure regulator, 0.01 percent to 0.3 percent of antiseptic/bacteriostat, pH value regulator and water. In a preparation method, the materials are weighted according to the percentage; the levofloxacin tropane is solved in injection water, the hydrophilic polymer material is added under the stirring state, and the solution is stood over a night; the adjuvant such as the humectant and the like is added, and the pH value is adjusted as 4 to 9; the solution is filtered, the injection water is added to the total quantity, and the ophthalmic in-situ jelly is obtained. The ophthalmic in-situ jelly has the advantages of uniform and smooth quality, proper viscosity, convenient use, exact dosage, and long-term uniform distribution on the surface of eye cornea; besides, the jelly causes no hypersusceptibility and irritation, no blurred vision, can effectively prolong the acting time of the medicine on the eye cornea, and has wide application prospect.

Radiopharmaceutical compounds are disclosed. A tropane compound is linked through the N atom at the 8-position to a chelating ligand capable of complexing technetium or rhenium to produce a neutral labeled complex that selectively binds to the dopamine transporter over the serotonin transporter with a ratio of 10 or more. These compounds can be prepared as separate diastereoisomers as well as a mixture of diastereoisomers. Also disclosed are radiopharmaceutical kits for preparing the labeled radiopharmaceutical compounds.

The invention relates to an automatic synthesis method of [11C] CH3Br and an automatic synthesis system thereof. The mixed gas of 0.5% O2 and 99.5% N2 is used as a target gas to produce 11CO2 by a circular accelerator through 14N (p, a) 11C nuclear reaction. 11CO2 can generate 11CH3Br by LiAlH4 reduction, hydrolysis and brominating reaction. A PET-CS-II-IT-IllCH3I synthesis module or a similar synthesis module is adopted for synthesis. [11C] CH3Br is further transformed to [11CH3] Triflate in a heated CF3SO3Ag/graphite column, and can be further used in methylation reaction to prepare [11C] methyl-N-2beta-methyl ester-3beta-(4- fluorine- phenyl) tropane. [11C] CH3Br can be used in methylation reaction to prepare 11C labeled positron medicine containing N-11CH3, O-11CH3 and S-11CH3 bonds, such as S-[11CH3]-L-methionine, (S-[11CH3])-L-cysteine and (N-[11CH3]) sinkaline and [11C] methyl-N-2beta- methyl ester-3beta-(4-fluorine- phenyl) tropane. The invention can realize the automatic synthesis of 11 CH3Br, can realize automatic synthesis, short synthesis time, high radiochemical yield and high purity quotient of radiochemical products, and can realize the automated production of 11C labeled positron medicine by further using methylation reaction.

The invention relates to the use of a monoamine neurotransmitter re-uptake inhibitor comprising a 2,3-disubstituted tropane moiety, or a tautomer, a pharmaceutically acceptable salt, solvate, or physiologically functional derivative thereof for a medicament for the for the sustained reduction of body weight.

The present invention relates to stabilised technetium and rhenium metal complex compositions comprising a radioprotectant and a radiometal complex of a tropane-tetradentate chelating agent conjugate, wherein the radiometal complex is neutral. Radiopharmaceuticals comprising the stabilised metal complex compositions, and kits for the preparation of the radiopharmaceuticals are also described.

Radiopharmaceutical compounds are disclosed. A tropane compound is linked through the N atom at the 8-position to a chelating ligand capable of complexing technetium or rhenium to produce a neutral labeled complex that selectively binds to the dopamine transporter over the serotonin transporter with a ratio of 10 or more. These compounds can be prepared as separate diastereoisomers as well as a mixture of diastereoisomers. Also disclosed are radiopharmaceutical kits for preparing the labeled radiopharmaceutical compounds.

A diagnostic formulation is provided comprising a tropane having a radioactive concentration of at least 1.6 mCi/mL at least about 51 hours post creation. The diagnostic formulation optionally comprises a radiolabeled dopamine transporter (DAT) ligand useful in the diagnosis of Parkinson's disease (PS). One example of a radiolabeled dopamine transporter (DAT) ligand example is [¹²³I]-2β-carbomethoxy-3β-(4-flurophenyl)-N-(3-iodo-E-allyl) nortropane.

The invention provides novel cocaine analogs. The invention also provides a method of preparing cocaine analogs with control over the substituents installed at the C-1, C-2, C-3, C-4 and N-8 positions of the tropane bicyclic scaffold. The invention further provides methods of providing anesthesia, blocking reuptake of a monoamine neurotransmitter, and treating depression, by administering to a subject in need of such treatment a pharmaceutical composition comprising a compound of the invention.

The invention belongs to the technical field of pesticides and particularly relates to an agent composition containing metaldehyde and tropane alkali and application thereof. The effective components of the agent composition are the metaldehyde and the tropane alkali, wherein the mass ratio of the metaldehyde to the tropane alkali is 1-30 to 0.001-3. In the composition, the tropane alkali is firstly applied to a snail killing pesticide, does not produce antagonism after being mutually mixed blended with the effective component metaldehyde, has a very good synergic effect and is obviously higher than a single agent in preventing effect, the snail killing efficiency is high, the usage dosage and usage times of agents are decreased, the economic cost is saved, too fast production of agent resistance is avoided, the lasting period of the agents is prolonged, agent residues in agricultural products and the environment are decreased, and environmental sustainable development is promoted. The composition has the special effect on snail killing.

The technetium [99m Tc] cachet pharmaceutical case for the 2beta- [N, N'-(2-mercapto ethyl) ethylenediamine] methyl-3beta-(4- chlorphenyl) tropane (in the following, using TRODAT-1 as abbreviation), relating to technique field of single photon emission computer tomography (SPECT) imaging agent. The invention provides a medicine case formulation for the TRODAT-1, the operation is simple and the marking rate is stable and larger than 90% when the medicine case is used for the mark of [99mTc]. The medicine is prepared through a certain composition of TRODAT-1, stannous salt, gluceplate, edetate and pH buffering agent. There is no identical report of the medicine case raised in this invention in the international.

The present invention describes a method for the treatment of attention deficit hyperactivity disorder (ADHD), conduct disorder, alcohol addiction, tobacco addiction, nicotine addiction, parkinsonism including Parkinson's disease, female and male orgasmic disorders, female and male sexual arousal disorders, hypoactive sexual desire disorder, and disorders characterized by anxiety and/or depression. In this method, a therapeutically effective, nontoxic dose of a 4′,4″-substituted 3α-(diphenylmethoxy) tropane analog or a pharmaceutically acceptable salt thereof is administered to the patient in need of such treatment.

The present invention relates to the use of tropane derivatives having dopamine reuptake inhibitor activity for the treatment of diseases associated with reduced blood flow to the brain or with instances of a temporary break in blood supply to the brain, such as ischemic diseases.

The present invention provides novel tropane compounds and methods for their use.